VEGFA and non-small cell lung carcinoma: Bevacizumab is the first US Food & Drug Administration (FDA)-approved recombinant humanized anti-VEGF monoclonal antibody for the treatment of non-small cell lung cancer (NSCLC), metastatic breast cancer, metastatic colorectal cancer, and other solid tumors [9].